ArQule Announces Dosing In Registrational Trial Of FGFR Inhibitor Derazantinib

ArQule, Inc. (ARQL) on Tuesday announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib or ARQ 087 in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma or iCCA.

from RTT - Biotech http://ift.tt/2iCCw4d
via IFTTT